{"id":255589,"date":"2026-07-13T04:27:51","date_gmt":"2026-07-13T01:27:51","guid":{"rendered":"https:\/\/1kitap1.com\/en\/cancer-drug-discovery-jie-jack-li\/"},"modified":"2026-07-13T04:27:51","modified_gmt":"2026-07-13T01:27:51","slug":"cancer-drug-discovery-jie-jack-li","status":"publish","type":"post","link":"https:\/\/1kitap1.com\/en\/cancer-drug-discovery-jie-jack-li\/","title":{"rendered":"Cancer Drug Discovery – Jie Jack Li"},"content":{"rendered":"
\"<\/figure>\n

\u23ce Born in 1925 to a college professor father and a high school English teacher mother, Janet Rowley graduated from college at age 19. Having secured an admission to the Medical School at the University of Chicago, she had to wait nine months because the quota for three women out of a class of 68 was full. In medical school, she fell in love with a classmate Donald Rawley and they married immediately after graduation in 1948. Donald became a professor of pathology at the University of Chicago and Janet worked part time, spending the next 20 years raising their four sons while managing working three days a week.20 Accompanying her husband for a stint of sabbatical in England, Janet Rowley learned the new banding methods for better visualization of characteristic banding patterns of chromosomes.<\/p>\n

Back at the University of Chicago she studied the cells of CML patients using the new chromosome banding technique. In 1972, she observed that chromosome 22 was indeed shorter as reported by Nowell and Hungerford. But chromosome 9 was longer than that in normal cells. The staining of the extra piece of material on chromosome 9 resembled that of the missing piece of chromosome 22. Rowley proposed that the Philadelphia chromosome resulted from a mutation, where genetic material between chromosome 9 and 22 swapped.<\/p>\n

The Philadelphia chromosome underwent a reciprocal translocation (Figure 3.5), not deletion as Hungerford and Nowell initially contemplated in 1960. It was the first evidence that the broken chromosome was the cause of When Rowley submitted her paper to The New England Journal of Medicine for publication, it was promptly rejected.<\/p>\n

She had to publish it on a less prestigious journal. In 1973, she submitted her paper on groundbreaking observation of reciprocal translocation as the sole author to Nature. It was eventually published, but not until after six months of intense scrutiny. The response for the paper was lukewarm because many thought the chromosomal translocation was the result of the leukemia, thus of little significance.<\/p>\n

The reality is that the chromosomal translocation is present in nearly all bone marrow cells of CML patients.<\/p>\n

\n

History is an erudite teacher, from which we can learn invaluable lessons, both positive and negative. This is especially true for drug discovery and development. While creativity demands we think outside of the box, past successes and failures in creating medicines are gifts that keep on giving. Creation of human medicines involves many scientific and medical disciplines and history is our indispensable resource of institutional knowledge. This volume in a new series sheds light on successes to emulate and pitfalls to avoid in oncology drug discovery.<\/p>\n

The series editor blends education with engaging content for aspiring drug developers and helps to foster a deeper understanding. Key Features It aims to integrate biology, chemistry, medicine, and history, which mirrors the multidisciplinary nature of drug development. By targeting the next generation drug developers and making efforts to include narrative and historical elements, it differentiates itself from pure technical texts. Using history to contextualize drug discovery helps readers to understand why certain strategies worked or failed.<\/p>\n

The inclusion of chemical structures in Chapter 8 makes the book more substantial for scientists with a chemistry background. The focus on novel approaches enhances the relevance of the book for the future. Jie Jack Li is an established chemist with over 30 years of experience in both medicinal chemistry and process chemistry.<\/p>\n

He is also renowned as an author or co-author of 34 peer-reviewed articles, 12 patents, and 35 books. Dr. Li worked at Pfizer, BMS, and Revolution Medicines in oncology, antivirals, metabolic disease, CNS, anti-inflammatory, and dermatology, targeting enzymes, receptors, and ion channels. Dr. Li was also a professor at the University of San Francisco for four years, teaching organic and medicinal chemistry. He earned his PhD from Indiana University and was a post-doctoral fellow at MIT.<\/p>\n

1kitap1.com\/en Pillars of Progress in Drug Discovery Series Editor: Jie Jack Li, Adjunct Professor, Medicinal Chemistry, University of Michigan History is an erudite teacher, from which we can learn invaluable lessons, both positive and negative. This is especially true for drug discovery and development. While creativity demands we think outside of the box, past successes and failures in creating medicines are gifts that keep on giving. Creation of human medicines involves so many scientific and medical disciplines that history is our indispensable resource of institutional knowledge.<\/p>\n

This book series sheds light on successes to emulate and pitfalls to avoid in drug discovery. The series editor blends education with engaging content for aspiring drug developers and helps to foster a deeper understanding.<\/p>\n<\/blockquote>\n

This is a short excerpt from the opening of “” by Unknown, quoted for review and introduction purposes. All rights belong to the copyright holders.<\/em><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n